1,107 research outputs found
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
No full textFrancesco Facchinetti, Paola Bordi, Alessandro Leonetti, Sebastiano Buti, Marcello Tiseo Medical Oncology Unit, University Hospital of Parma, Parma, Italy Abstract: Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents an affirmed reality in the treatment of advanced non-small-cell lung cancer (NSCLC) patients. Atezolizumab, an anti-PD-L1 agent, figures among the drugs that provide previously unenvisaged outcomes in the pretreated setting of metastatic NSCLC. Increasing evidence vouches for the early administration of PD-1/PD-L1 blockers in untreated patients, encompassing atezolizumab combinations with chemotherapy and the anti-angiogenic agent bevacizumab. Moreover, the development of atezolizumab allowed to derive several hints regarding clinical and immunological factors predictive of its activity and efficacy, some of them exclusive among this class of drugs. This review provides an overview of atezolizumab development throughout clinical trials toward its applicability in the routine practice, with a particular focus on patient selection based on clinical and immune-related factors. Keywords: non-small cell lung cancer, NSCLC, immune checkpoint blockers, ICB, PD-1, PD-L1, atezolizumab development, biomarker
Does Liver derived ANGPTL3 play a role in cardiometabolic risk? Current evidence and future perspectives
No full textIs the door open to further investigation with antiangiogenesis in SCLC?
No full textPulmonary and Respiratory Medicin
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance
No full textOsimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approximately 10 months. Mechanisms determining progression of disease are heterogeneous and not fully understood. EGFR-dependent resistance mechanisms (such as new EGFR mutations), bypass pathway activation [as erb-b2 receptor tyrosine kinase 2 (HER2) or MET amplification] and histological transformation [in small cell lung cancer (SCLC)] have been reported, similarly to previous generation TKIs. Here, we review principle mechanisms of innate and acquired resistance described in literature both in clinical and preclinical settings during NSCLC treatment with third-generation EGFR-TKIs
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials
No full textBackground Relapsed small cell lung cancer (SCLC) is classified into sensitive or resistant according to treatment-free interval (TFI) longer or shorter than 60 (criteria 1) or 90 (criteria 2) days. However, these criteria are based on small old studies and are inconsistent among different studies. The present study aimed at validating these criteria and assessing additional clinical parameters predictive of response rate (RR) and overall survival (OS). Patients and methods A database of six GlaxoSmithKline-sponsored trials of intravenous topotecan-based second-line chemotherapy was analysed. Validation of sensitive/resistant definition was performed on the entire dataset (631 patients), while study of additional parameters and development of prognostic model was conducted dividing the database into derivation and validation sets. Results The association between criterion 1 or 2 and RR was confirmed. Changing TFI cut-off or adding response to first-line did not improve accuracy. In addition to TFI (P = 0.007), only presence of liver metastasis (P = 0.046) was found to affect the probability of objective response. TFI, age, liver metastases, performance status (PS), albumin, haemoglobin and sodium levels were identified as independent prognostic factors for OS. A prognostic model, based on these variables, was able to separate relapsed SCLC into low versus high risk categories (median OS 41.4 versus 20.0 weeks). Conclusions This study confirms the value of standard criteria for relapsed SCLC outcome prediction. Patients with TFI < 60 days are refractory to second-line chemotherapy and have poor OS. Patients with liver metastasis and/or PS2 and/or low albumin, regardless of TFI, have similarly poor outcome.© 2014 Elsevier Ltd. All rights reserved
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
No full text
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin
No full textAbstract not availableMarcello Tiseo, Elisa Giovannetti, Carmelo Tibaldi, Andrea Camerini, Francesco Di Costanzo, Fausto Barbieri, Jacobus A. Burgers, Andrew Vincent, Godefridus J. Peters, Egbert F. Smit, Andrea Ardizzon
sj-jpg-1-onc-10.1177_11795549211043427 – Supplemental material for Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study
No full textSupplemental material, sj-jpg-1-onc-10.1177_11795549211043427 for Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study by Sebastiano Buti, Fabiana Perrone, Teresa Zielli, Giulia Mazzaschi, Chiara Casartelli, Alessandro Leonetti, Gianluca Milanese, Mario Silva, Roberta Eufrasia Ledda, Antonino Musolino, Francesca Pucci, Melissa Bersanelli and Marcello Tiseo in Clinical Medicine Insights: Oncology</p
First-Line Chemotherapy Treatment of Advanced Non–Small-Cell Lung Cancer: Does Cisplatin versus Carboplatin Make a Difference?
No full textn
- …
